
3 Snacks and Sweets Brand, Aluminium Producer and Pharmaceuticals Maker Stocks With a Strong Future Roadmap: Bikaji Foods International, National Aluminium Company and Ipca Laboratories
Bikaji Foods International, National Aluminium Company and Ipca Laboratories: ROE of 14.2% to 26.8% and FY22 to FY26 revenue CAGR of 6.3% to 17.1%. Prices as of 17 Nov 2026.
Updated: 18 Nov 2026 • 3:27 pm
Posted by:

Quick Answer
The three snacks, aluminium and drug maker stocks to watch are Bikaji Foods International, National Aluminium Company and Ipca Laboratories. Their return on equity ranges from 14.2% to 26.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.3% to 17.1%. National Aluminium Company has the highest return on equity at 26.8%, while Bikaji Foods International has the fastest revenue growth at 17.1% a year. Prices are based on the 17 November 2026 close, and this article is educational, not investment advice.
Snacks, aluminium and drug maker stocks give investors a way to track businesses that sit close to everyday demand in India. Bikaji Foods International, National Aluminium Company and Ipca Laboratories cover a snacks and sweets brand, an aluminium producer and a pharmaceuticals maker.
This list covers three snacks, aluminium and drug maker stocks with complete current figures: Bikaji Foods International, National Aluminium Company and Ipca Laboratories. Every figure comes from the latest reported financials and the 17 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Snacks, Aluminium and Drug Maker Stocks?
Snacks, aluminium and drug maker stocks are listed companies that make namkeen, sweets and packaged snacks for households, mine bauxite and produce aluminium and alumina, and make medicines and active ingredients for India and global markets. Their earnings depend on snack demand, aluminium prices and medicine demand.
Snacks, Aluminium and Drug Maker Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Bikaji Foods International | 489.05 | 11,686 | 45.8 | 33.9 | 16.1 | 0.19 |
| National Aluminium Company | 320.9 | 58,387 | 8.7 | 11.6 | 26.8 | 0.00 |
| Ipca Laboratories | 1,834.4 | 46,050 | 33.5 | 36.0 | 14.2 | 0.10 |
On valuation, National Aluminium Company and Ipca Laboratories trade at a P/E below the industry P/E, while Bikaji Foods International trades above it, which reflects the growth the market already expects. Readers comparing snacks, aluminium and drug maker stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in snacks, aluminium and drug maker stocks can use the coming numbers to test whether growth is holding.
Why Do Snacks, Aluminium and Drug Maker Stocks Have a Strong Roadmap in India?
Snacks, aluminium and drug maker stocks have a strong roadmap in India because steady demand for packaged snacks, wider use of aluminium in vehicles and power lines and rising demand for medicines keep widening the market for these companies.
- Snacks. Households buy trusted namkeen brands.
- Aluminium. Vehicles and power lines use light metal.
- Pharmaceuticals. Patients need dependable formulations.
Why Bikaji Foods International Features Among These Snacks, Aluminium and Drug Maker Stocks
Among the snacks, aluminium and drug maker stocks on this list, Bikaji Foods International, headquartered in Bikaner, makes traditional Indian snacks such as bhujia and namkeen, along with sweets, papad and other packaged foods.
Revenue rose from Rs 1,621 crore in FY22 to Rs 3,045 crore in FY26, a compound annual growth rate of 17.1%. Net profit grew from Rs 76.0 crore in FY22 to Rs 254 crore in FY26, which works out to a compound annual growth rate of 35.3%.
In the June 2026 quarter, revenue grew 12.8% year on year to Rs 747 crore, while net profit rose 1.6% to Rs 59.5 crore. The company has a return on equity of 16.1%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 11,686 crore. The stock trades at a P/E of 45.8, above the industry P/E of 33.9.
Roadmap: The company is pushing into new states, building modern trade and e-commerce presence, and widening its range of packaged sweets and snacks. A larger distribution reach lets it carry more products into every store it supplies.
What to watch: Track distribution expansion and input costs for edible oils and potatoes.
Why National Aluminium Company Features Among These Snacks, Aluminium and Drug Maker Stocks
Among the bhujia brand, metal producer and formulation shares on this list, National Aluminium Company, known as NALCO, is a public sector firm that mines bauxite, refines alumina and produces aluminium, with captive power generation in Odisha.
In the June 2026 quarter, revenue grew 39.3% year on year to Rs 5,476 crore, while net profit rose 90.9% to Rs 2,003 crore. Revenue rose from Rs 14,478 crore in FY22 to Rs 18,509 crore in FY26, a compound annual growth rate of 6.3%.
Net profit grew from Rs 2,951 crore in FY22 to Rs 5,797 crore in FY26, which works out to a compound annual growth rate of 18.4%. The company has a return on equity of 26.8%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 58,387 crore. The stock trades at a P/E of 8.7, below the industry P/E of 11.6.
Roadmap: The company is one of the lowest-cost integrated aluminium producers and plans to expand its mine, refinery and smelter capacity. A debt-free balance sheet and strong cash flows support these investments.
What to watch: Follow aluminium and alumina price trends and the pace of its expansion projects.
Why Ipca Laboratories Features Among These Snacks, Aluminium and Drug Maker Stocks
Among the three companies on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.
The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0.
Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore.
Roadmap: The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.
What to watch: Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.
Bikaji Foods International vs National Aluminium Company vs Ipca Laboratories on Key Financials
The table below sets the three snacks, aluminium and drug maker stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Bikaji Foods International | 1,621 | 3,045 | 17.1% | 254 | 8.4% |
| National Aluminium Company | 14,478 | 18,509 | 6.3% | 5,797 | 31.3% |
| Ipca Laboratories | 5,896 | 9,821 | 13.6% | 1,191 | 12.1% |
National Aluminium Company posts the highest return on equity in this group at 26.8%. National Aluminium Company has the largest FY26 revenue at Rs 18,509 crore, and Bikaji Foods International shows the fastest revenue growth with a 17.1% compound annual rate. A useful habit with snacks, aluminium and drug maker stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several packaged namkeen, aluminium and medicines stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Bikaji Foods International | 663 | 747 | 12.8% |
| National Aluminium Company | 3,930 | 5,476 | 39.3% |
| Ipca Laboratories | 2,342 | 2,813 | 20.2% |
Key Risks to Check Before Investing in Snacks, Aluminium and Drug Maker Stocks
Every theme carries risks that deserve a check before any decision. For these snacks, aluminium and drug maker stocks, the main points are: Long-term bhujia brand, metal producer and formulation shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Raw material costs. Ingredient and packaging prices can move margins.
- Pricing pressure. Generic prices can change by market.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter snacks, aluminium and drug maker stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Snacks, Aluminium and Drug Maker Stocks
Snacks, aluminium and drug maker stocks work best when investors track growth, valuation and return on equity side by side. Bikaji Foods International, National Aluminium Company and Ipca Laboratories each have a clear plan to grow. Based on the 17 November 2026 close, Bikaji Foods International trades at Rs 489.05, National Aluminium Company at Rs 320.9 and Ipca Laboratories at Rs 1,834.4. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these snacks, aluminium and drug maker stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track snacks, aluminium and drug maker stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are snacks, aluminium and drug maker stocks?
Ans. Snacks, aluminium and drug maker stocks are listed companies that make namkeen, sweets and packaged snacks for households, mine bauxite and produce aluminium and alumina, and make medicines and active ingredients for India and global markets. Their earnings depend on snack demand, aluminium prices and medicine demand. This list looks at three of them, Bikaji Foods International, National Aluminium Company and Ipca Laboratories, using reported FY22 to FY26 financials and the 17 November 2026 closing prices.
Which snacks, aluminium and drug maker stocks are covered in this list?
Ans. This list covers Bikaji Foods International, National Aluminium Company and Ipca Laboratories. Based on the 17 November 2026 close, Bikaji Foods International traded at Rs 489.05, National Aluminium Company at Rs 320.9 and Ipca Laboratories at Rs 1,834.4. Their return on equity ranges from 14.2% to 26.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.3% to 17.1%.
Why do snacks, aluminium and drug maker stocks have a strong future roadmap in India?
Ans. Snacks, aluminium and drug maker stocks have a strong roadmap in India because steady demand for packaged snacks, wider use of aluminium in vehicles and power lines and rising demand for medicines keep widening the market for these companies. The main drivers are as follows. Snacks. Households buy trusted namkeen brands. Aluminium. Vehicles and power lines use light metal. Pharmaceuticals. Patients need dependable formulations. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Bikaji Foods International performed financially?
Ans. Revenue rose from Rs 1,621 crore in FY22 to Rs 3,045 crore in FY26, a compound annual growth rate of 17.1%. Net profit grew from Rs 76.0 crore in FY22 to Rs 254 crore in FY26, which works out to a compound annual growth rate of 35.3%. In the June 2026 quarter, revenue grew 12.8% year on year to Rs 747 crore, while net profit rose 1.6% to Rs 59.5 crore. The company has a return on equity of 16.1%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 11,686 crore. The stock trades at a P/E of 45.8, above the industry P/E of 33.9. Looking ahead, the company is pushing into new states, building modern trade and e-commerce presence, and widening its range of packaged sweets and snacks. A larger distribution reach lets it carry more products into every store it supplies.
How has National Aluminium Company performed financially?
Ans. Revenue rose from Rs 14,478 crore in FY22 to Rs 18,509 crore in FY26, a compound annual growth rate of 6.3%. Net profit grew from Rs 2,951 crore in FY22 to Rs 5,797 crore in FY26, which works out to a compound annual growth rate of 18.4%. In the June 2026 quarter, revenue grew 39.3% year on year to Rs 5,476 crore, while net profit rose 90.9% to Rs 2,003 crore. The company has a return on equity of 26.8%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 58,387 crore. The stock trades at a P/E of 8.7, below the industry P/E of 11.6. Looking ahead, the company is one of the lowest-cost integrated aluminium producers and plans to expand its mine, refinery and smelter capacity. A debt-free balance sheet and strong cash flows support these investments.
How has Ipca Laboratories performed financially?
Ans. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.
What risks should investors check before buying snacks, aluminium and drug maker stocks?
Ans. Investors should check a few risks before buying snacks, aluminium and drug maker stocks. Raw material costs. Ingredient and packaging prices can move margins. Pricing pressure. Generic prices can change by market. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of snacks, aluminium and drug maker stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 17 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
Recent Articles

Top Large-Cap Cement Stocks Compared: UltraTech Cement vs Grasim vs JK Lakshmi Cement vs Ramco Cements vs Heidelberg Cement India on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Nifty Pharma Stocks Compared: Dr Reddy's vs Lupin vs Zydus Lifesciences vs Biocon vs Natco Pharma on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Specialty Chemical Stocks Compared: SRF vs Navin Fluorine vs Atul vs Vinati Organics vs Clean Science on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Paints Stocks Compared: Asian Paints vs Berger Paints vs Kansai Nerolac vs Indigo Paints vs JSW Dulux on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Top Large-Cap Cement Stocks Compared: UltraTech Cement vs Grasim vs JK Lakshmi Cement vs Ramco Cements vs Heidelberg Cement India on Price, Valuation, Q2 FY27 Results and Risks
Top Nifty Pharma Stocks Compared: Dr Reddy's vs Lupin vs Zydus Lifesciences vs Biocon vs Natco Pharma on Price, Valuation, Q2 FY27 Results and Risks
Top Specialty Chemical Stocks Compared: SRF vs Navin Fluorine vs Atul vs Vinati Organics vs Clean Science on Price, Valuation, Q2 FY27 Results and Risks
Top Paints Stocks Compared: Asian Paints vs Berger Paints vs Kansai Nerolac vs Indigo Paints vs JSW Dulux on Price, Valuation, Q2 FY27 Results and Risks
Top Diagnostics Stocks Compared: Dr Lal PathLabs vs Metropolis vs Thyrocare vs Krsnaa Diagnostics vs Vijaya Diagnostic on Price, Valuation, Q2 FY27 Results and Risks

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





